Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study

Andrii R Korol, Oleg S Zadorozhnyy, Volodymyr O Naumenko, Taras B Kustryn, Nataliya V Pasyechnikova The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine, Odessa, Ukraine Purpose: To determine the efficacy of intravitreal aflibercept inject...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Korol AR, Zadorozhnyy OS, Naumenko VO, Kustryn TB, Pasyechnikova NV
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	aflibercept angiogenesis inhibitors choroidal neovascularization eye diseases pathologic myopia Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/617d548fbf0843569ab0adfeb90124c4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:617d548fbf0843569ab0adfeb90124c4
record_format	dspace
spelling	oai:doaj.org-article:617d548fbf0843569ab0adfeb90124c42021-12-02T03:42:03ZIntravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study1177-5483https://doaj.org/article/617d548fbf0843569ab0adfeb90124c42016-11-01T00:00:00Zhttps://www.dovepress.com/intravitreal-aflibercept-for-the-treatment-of-choroidal-neovasculariza-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Andrii R Korol, Oleg S Zadorozhnyy, Volodymyr O Naumenko, Taras B Kustryn, Nataliya V Pasyechnikova The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine, Odessa, Ukraine Purpose: To determine the efficacy of intravitreal aflibercept injections for the treatment of patients with choroidal neovascularization (CNV) associated with pathologic myopia. Methods: In this uncontrolled, prospective cohort study, 31 eyes of 30 consecutive patients affected by CNV associated with pathologic myopia were treated with intravitreal aflibercept (2 mg) as needed following two initial monthly doses and observed over a 12-month follow-up period. The primary endpoint was change in best-corrected visual acuity (BCVA) at month 12, while central retinal thickness (CRT) on optical coherence tomography (OCT), neovascularization activity on fluorescein angiography, the number of aflibercept injections administered, and safety were examined as secondary endpoints. Results: Patients received a mean of 2.6 intravitreal aflibercept injections over the 12-month study period. Compared with baseline, BCVA improved significantly at all time points (P<0.05). Mean (standard deviation [SD]) decimal BCVA was 0.2 (0.1) at baseline and 0.35 (0.16) at month 12. The greatest improvement in BCVA was seen within the first 2 months (P=0.01). Mean (SD) CRT on OCT decreased from 285 (62) µm at baseline to 227 (42) µm (P=0.01) at month 12. There was a continuous decrease in mean CRT on OCT over time. No cases of endophthalmitis, uveitis, stroke, or retinal detachment were noted. No patient demonstrated an intraocular pressure >20 mmHg during any study visit. Conclusion: The 12-month results of intravitreal aflibercept for myopic CNV using an as-needed regimen were positive, showing benefits in visual and anatomic outcomes and an acceptable tolerability profile. Keywords: aflibercept, angiogenesis inhibitors, choroidal neovascularization, eye diseases, pathologic myopiaKorol ARZadorozhnyy OSNaumenko VOKustryn TBPasyechnikova NVDove Medical Pressarticleafliberceptangiogenesis inhibitorschoroidal neovascularizationeye diseasespathologic myopiaOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 10, Pp 2223-2229 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	aflibercept angiogenesis inhibitors choroidal neovascularization eye diseases pathologic myopia Ophthalmology RE1-994
spellingShingle	aflibercept angiogenesis inhibitors choroidal neovascularization eye diseases pathologic myopia Ophthalmology RE1-994 Korol AR Zadorozhnyy OS Naumenko VO Kustryn TB Pasyechnikova NV Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study
description	Andrii R Korol, Oleg S Zadorozhnyy, Volodymyr O Naumenko, Taras B Kustryn, Nataliya V Pasyechnikova The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine, Odessa, Ukraine Purpose: To determine the efficacy of intravitreal aflibercept injections for the treatment of patients with choroidal neovascularization (CNV) associated with pathologic myopia. Methods: In this uncontrolled, prospective cohort study, 31 eyes of 30 consecutive patients affected by CNV associated with pathologic myopia were treated with intravitreal aflibercept (2 mg) as needed following two initial monthly doses and observed over a 12-month follow-up period. The primary endpoint was change in best-corrected visual acuity (BCVA) at month 12, while central retinal thickness (CRT) on optical coherence tomography (OCT), neovascularization activity on fluorescein angiography, the number of aflibercept injections administered, and safety were examined as secondary endpoints. Results: Patients received a mean of 2.6 intravitreal aflibercept injections over the 12-month study period. Compared with baseline, BCVA improved significantly at all time points (P<0.05). Mean (standard deviation [SD]) decimal BCVA was 0.2 (0.1) at baseline and 0.35 (0.16) at month 12. The greatest improvement in BCVA was seen within the first 2 months (P=0.01). Mean (SD) CRT on OCT decreased from 285 (62) µm at baseline to 227 (42) µm (P=0.01) at month 12. There was a continuous decrease in mean CRT on OCT over time. No cases of endophthalmitis, uveitis, stroke, or retinal detachment were noted. No patient demonstrated an intraocular pressure >20 mmHg during any study visit. Conclusion: The 12-month results of intravitreal aflibercept for myopic CNV using an as-needed regimen were positive, showing benefits in visual and anatomic outcomes and an acceptable tolerability profile. Keywords: aflibercept, angiogenesis inhibitors, choroidal neovascularization, eye diseases, pathologic myopia
format	article
author	Korol AR Zadorozhnyy OS Naumenko VO Kustryn TB Pasyechnikova NV
author_facet	Korol AR Zadorozhnyy OS Naumenko VO Kustryn TB Pasyechnikova NV
author_sort	Korol AR
title	Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study
title_short	Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study
title_full	Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study
title_fullStr	Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study
title_full_unstemmed	Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study
title_sort	intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/617d548fbf0843569ab0adfeb90124c4
work_keys_str_mv	AT korolar intravitrealafliberceptforthetreatmentofchoroidalneovascularizationassociatedwithpathologicmyopiaapilotstudy AT zadorozhnyyos intravitrealafliberceptforthetreatmentofchoroidalneovascularizationassociatedwithpathologicmyopiaapilotstudy AT naumenkovo intravitrealafliberceptforthetreatmentofchoroidalneovascularizationassociatedwithpathologicmyopiaapilotstudy AT kustryntb intravitrealafliberceptforthetreatmentofchoroidalneovascularizationassociatedwithpathologicmyopiaapilotstudy AT pasyechnikovanv intravitrealafliberceptforthetreatmentofchoroidalneovascularizationassociatedwithpathologicmyopiaapilotstudy
_version_	1718401666848391168

Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study

Ejemplares similares